The Pharma Data

APRIL 9, 2021

today announced it will report first quarter 2021 financial results Thursday, April 22, 2021, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. To access the live webcast, please go to the investors section of Biogen’s website at [link].

Biosimilars 52

Biosimilars Disease Therapies Treatment 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We The series of promising pipeline updates included the data from the landmark ZUMA-7 study for the treatment of second-line large B-cell lymphoma.

Science 52

Science Production Treatment FDA 52

The Pharma Data

JANUARY 4, 2021

5, 2021 07:00 UTC. February 12, 2021. March 25, 2021. 2021 First Quarter Financial Update. April 21, 2021. 2021 Second Quarter Financial Update. July 21, 2021.

Treatment 52

Treatment Trials Clinical Trials Disease 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research DNA 52

The Pharma Data

MARCH 5, 2021

Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference. AD/PD Webcast Schedule Details: Wednesday, March 10, 2021, 6:45 a.m. About Aducanumab.

Licensing 52

Licensing Licensing Biosimilars Disease 52

The Pharma Data

JULY 29, 2021

Second-Quarter 2021 Revenues of $19.0 Billion The 10% Operational Growth Excluding BNT162b2(1) in Second-Quarter 2021 Builds on the 6% Operational Growth Delivered by the Comparable Business in Second-Quarter 2020 Second-Quarter 2021 Reported Diluted EPS(2) of $0.98, Adjusted Diluted EPS(3) of $1.07

Biosimilars 52

Biosimilars Vaccine Production International 52

Eye on FDA

JULY 19, 2021

But here is what we see looking at the first 6 months 2021, and comparing it to mid-years past. Last year the agency issued over 400 releases on a range of topics (65 percent of releases were related to COVID-190. Of the 153, only 33 of them were translated into Spanish.

FDA 93

FDA Vaccine Treatment Drugs 93

The Pharma Data

MAY 16, 2021

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) for National Health Service use as first-line treatment for adults with untreated metastatic colorectal cancers with high levels of microsatellite instability or DNA mismatch repair deficiency. months, compared with just 8.2

Treatment 52

Treatment DNA Drugs 52

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. Key results include: Total revenues increased 5% to $6.5 on a non-GAAP basis.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

NOVEMBER 23, 2021

Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. 2 FL is the most common idle ( slow growing) form ofnon-Hodgkin carcinoma, a type of blood cancer, which frequently returns after original remedy.4

Treatment 52

Treatment Drugs Trials Production 52

The Pharma Data

DECEMBER 1, 2020

02, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial statements. MARSEILLE, France, Dec. . .

Cell Biology 52

Cell Biology Clinical Trials Production Licensing 52

The Pharma Data

JANUARY 10, 2021

The rollout of these treatments could therefore contribute significantly toward reducing pressures on hospitals over the coming weeks and months.”. We found that among critically ill adult patients — those receiving breathing support in intensive care — treatment with these drugs can improve their chances of survival and recovery.”.

Treatment 52

Treatment Government Hospitals Drugs 52

The Pharma Data

JUNE 18, 2021

1 The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress. 1 The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress. Efficacy data reported based on randomized treatment. RINVOQ 15 mg. (n=211).

Treatment 40

Treatment Therapies Clinical Trials Disease 40

Common Sense for Drug Policy Blog

OCTOBER 7, 2023

Given that the median duration of prison stay was only 16 days, excess risk of infection-related hospitalization after release may also reflect people seeking treatment outside prison for infections that initially developed before or during incarceration ( Lloyd et al., 2012 ; Joudrey et al., 2019 ; Treloar et al., times the risk, 95% CI 1.22-1.72)

Hospitals 52

Hospitals Treatment International Drugs 52

The Pharma Data

JANUARY 11, 2021

Treatment Success Seen With Antibiotics for Uncomplicated Appendicitis. 11, 2021 — For adults with uncomplicated acute appendicitis, treatment success rates ?65 The primary end point was treatment success (?65 The researchers found that the treatment success rate at one year was 70.2 © 2021 HealthDay.

Treatment 52

Treatment Hospitals Pharmaceuticals Research 52

The Pharma Data

JANUARY 12, 2021

After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques that are hallmarks of Alzheimer’s disease, according to Dr. Daniel Skovronsky, the company’s chief scientific officer. © 2021 HealthDay. Posted: January 2021. All rights reserved. Source link.

Clinical Trials 52

Clinical Trials Laboratories Trials Treatment 52

The Pharma Data

AUGUST 7, 2021

In June 2021, Wegovy , semaglutide 2.4 For the 2021 outlook, sales growth is now expected to be 10-13% at CER (previously 6-10%), and operating profit growth is now expected to be 9-12% at CER (previously 5-9%). ?? Lars Fruergaard Jørgensen, president and CEO: “We are pleased with the sales growth in the first half of 2021.

International 52

International Treatment FDA Therapies 52

The Pharma Data

APRIL 7, 2021

today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. . Key AbbVie abstracts and presentation details for the 2021 AAN Annual Meeting program are outlined below. Abstract Title. Presentation Details.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

FEBRUARY 8, 2021

PARIS – February 5, 2021 – Today, Sanofi holds a virtual investor event with key members of the Sanofi leadership team to share and discuss the overall progress in implementing the strategy in core parts of the business as well as the transformation of R&D. Key highlights to be presented at Capital Markets Day 2021.

Marketing 52

Marketing Clinical Trials Disease Vaccine 52

The Pharma Data

MARCH 16, 2021

We were able to make 16 diagnostic solutions available in record time and are working closely together with partners on developing and producing treatment options for COVID-19. Roche had already communicated on 18 January 2021 that shareholders would only be able to vote via the independent proxy. Source link:[link].

Pharmaceuticals 52

Pharmaceuticals Treatment Production 52

The Pharma Data

AUGUST 3, 2021

Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good business performance in all areas, despite ongoing impact of COVID-19. Our strong R&D pipeline has made further, decisive progress in the first half of 2021.

Research 52

Research Treatment Clinical Trials Production 52

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. © 2021 HealthDay. Posted: January 2021. Professional. WEDNESDAY, Jan.

Treatment 52

Treatment Trials Hospitals Virus 52

The Pharma Data

JANUARY 7, 2021

– January 8, 2021) – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase 2021 and will be presenting the strategic plan for long-term growth.

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — Nevro Corp (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. . REDWOOD CITY, Calif. , Internet Posting of Information. Internet Posting of Information.

Therapies 52

Therapies Treatment Production 52

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

APRIL 30, 2021

per share payable as of May 7, 2021. per share with payment as of May 7, 2021. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. Dividend of €3.20 Source link.

Government 40

Government Vaccine Treatment Disease 40

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. At ISTH, we are sharing data across all our innovative approaches and collectively, the data reinforce how our pipeline and portfolio may unlock new possibilities in the treatment of rare blood disorders.”. ePoster Abstract # OC48.2

Therapies 52

Therapies Pharmacokinetics RNA Treatment 52

The Pharma Data

APRIL 30, 2021

April 30, 2021 /PRNewswire/ — AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. “We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said Richard A. .

FDA 40

FDA Production Treatment International 40

The Pharma Data

JANUARY 21, 2021

21, 2021 — The arthritis drug tocilizumab doesn’t help hospital patients with severe COVID-19 , according to a new study that contradicts earlier research suggesting that it might aid recovery. © 2021 HealthDay. Posted: January 2021. THURSDAY, Jan. All rights reserved. Further Support and Information on COVID-19.

Treatment 52

Treatment Hospitals Drugs Trials 52

Eye on FDA

JANUARY 9, 2022

In that respect, 2021 was not a banner year. Digital and social media are a primary resource for getting healthcare information and discussing treatment, especially now in the age of COVID. The Numbers: Looking first at the quantity of enforcement, the numbers were low. This year there were 5 regulatory action letters issued by OPDP.

FDA 64

FDA Pharma Companies Pharmaceutical Companies Treatment 64

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. Session Date and Time: Sunday, April 11, 2021 2:00 PM – 3:45 PM ET.

Research 52

Research Clinical Trials Trials FDA Approval 52

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. ERLEADA ® is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC and for the treatment of patients with mCSPC. 10 months. [5]

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

JANUARY 7, 2021

With eight drugs awaiting regulatory approval and 26 projects in Phase III studies, Sanofi is on the cusp of a transformative year during 2021. The Bruton tyrosine kinase (BTK) inhibitors are expected to be key assets in a portfolio of the next generation of transformative treatments for autoimmune diseases. ricochet64/Shutterstock.

Disease 52

Disease Therapies Engineering Treatment 52

The Pharma Data

DECEMBER 13, 2020

Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma. Session Date and Time: 1/17/2021, 2:30 PM-3:15 PM (PST).

Small Molecule 40

Small Molecule FDA Clinical Trials DNA 40

The Pharma Data

JANUARY 4, 2021

Drug Industry Daily (DID) the premier online resource for savvy pharmaceutical professionals whose jobs depend on accurate knowledge about the daily activities of Congress, the FDA, other key regulators … and what their competitors are up to.

Treatment 52

Treatment Research Compliance FDA 52

National Institute on Drug Abuse: Nora's Blog

JULY 22, 2024

People with an opioid use disorder (OUD) urgently need treatment not just to protect them from overdosing but also to help them achieve recovery, but highly effective medications like buprenorphine and methadone remain underused. Almost all (99%) of those retained in treatment achieved remission. For instance, in 2021, the U.S.

Pharmacy 85

Pharmacy Treatment Community Pharmacies Trials 85